Free tool
FAERS Monitor: Mestinon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 015193 or its brand name (Mestinon, Pyridostigmine Bromide). Reports on generic versions are filed under their own applications.
Reports
7,620
Serious
5,403
71% of reports
Hospitalization
2,644
Death reported
526
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myasthenia gravis878
- fatigue781
- drug ineffective635
- asthenia614
- off label use598
- diarrhoea565
- headache537
- dyspnoea527
- nausea480
- muscular weakness410
- fall389
- dizziness344
- malaise317
- pain310
- diplopia296
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 65 |
| 2006 | 79 |
| 2007 | 78 |
| 2008 | 109 |
| 2009 | 114 |
| 2010 | 99 |
| 2011 | 138 |
| 2012 | 145 |
| 2013 | 121 |
| 2014 | 120 |
| 2015 | 221 |
| 2016 | 325 |
| 2017 | 311 |
| 2018 | 377 |
| 2019 | 499 |
| 2020 | 548 |
| 2021 | 438 |
| 2022 | 448 |
| 2023 | 718 |
| 2024 | 903 |
| 2025 | 951 |
| 2026 | 751 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,539 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravisSignal | 878 | 336.5 | 314.9 | 261,589 |
| diplopiaSignal | 296 | 31.8 | 28.4 | 8,709 |
| muscular weaknessSignal | 410 | 10.0 | 9.1 | 3,314 |
| astheniaSignal | 614 | 4.5 | 4.2 | 1,703 |
| fallSignal | 389 | 3.2 | 2.9 | 605 |
| fatigueSignal | 781 | 2.8 | 2.6 | 915 |
| dyspnoeaSignal | 527 | 2.6 | 2.4 | 518 |
| diarrhoeaSignal | 565 | 2.4 | 2.2 | 482 |
| headacheSignal | 537 | 2.4 | 2.2 | 434 |
| malaise | 317 | 2.0 | 1.8 | 160 |
| dizziness | 344 | 1.9 | 1.7 | 150 |
| off label use | 598 | 1.9 | 1.7 | 258 |
| nausea | 480 | 1.7 | 1.5 | 135 |
| pain | 310 | 1.4 | 1.2 | 35 |
| drug ineffective | 635 | 1.3 | 1.2 | 55 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.